Comparative Pharmacology
Head-to-head clinical analysis: CEFTRIAXONE AND DEXTROSE IN DUPLEX CONTAINER versus TAZIDIME.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFTRIAXONE AND DEXTROSE IN DUPLEX CONTAINER versus TAZIDIME.
CEFTRIAXONE AND DEXTROSE IN DUPLEX CONTAINER vs TAZIDIME
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ceftriaxone is a third-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby inhibiting peptidoglycan cross-linking. It has bactericidal activity against a broad range of gram-positive and gram-negative bacteria.
Ceftazidime inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity, and disrupting peptidoglycan cross-linking.
1-2 g intravenously or intramuscularly every 24 hours. Maximum dose: 4 g daily.
1 to 2 g IV/IM every 8 hours; maximum 6 g/day.
None Documented
None Documented
Terminal elimination half-life is approximately 5.8-8.7 hours in adults, prolonged to 12-24 hours in elderly, and up to 30-72 hours in neonates. No dose adjustment in renal impairment alone; adjust in severe hepatic impairment.
Clinical Note
moderateCeftazidime + Probenecid
"The serum concentration of Probenecid can be increased when it is combined with Ceftazidime."
Clinical Note
moderateCeftazidime + Picosulfuric acid
"The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Ceftazidime."
Clinical Note
moderateWarfarin + Ceftazidime
"Warfarin may increase the anticoagulant activities of Ceftazidime."
Clinical Note
moderatePhenprocoumon + Ceftazidime
1.9 hours (range 1.5-2.8 hours); prolonged in renal impairment (up to 20 hours in ESRD).
Renal (33-67% unchanged) and biliary (up to 40% as unchanged drug and microbiologically inactive metabolites); fecal elimination of unabsorbed drug is minimal. Dose adjustment required in combined renal and hepatic impairment.
Primarily renal (80-90% unchanged via glomerular filtration), biliary/fecal <5%.
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic
"Phenprocoumon may increase the anticoagulant activities of Ceftazidime."